Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MGC026 Dose Escalation
MGC026 · 1 trial · 22 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | MGC026 is a topoisomerase 1 inhibitor (TOP1i)-based ADC that targets B7-H3 administered IV every 3 weeks. |
| Cohort 2 | EXPERIMENTAL | - |
| Cohort 3 | EXPERIMENTAL | - |
| Cohort 4 | EXPERIMENTAL | - |
| Cohort 5 | EXPERIMENTAL | - |
| Cohort 6 | EXPERIMENTAL | - |
| Expansion cohort 1 | EXPERIMENTAL | - |
| Expansion cohort 2 | EXPERIMENTAL | - |
| Expansion cohort 3 | EXPERIMENTAL | - |
| Expansion cohort 4 | EXPERIMENTAL | - |
| Expansion Cohort 5 | EXPERIMENTAL | - |
| Expansion Cohort 6 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MGC026 Dose Escalation | BIOLOGICAL | Escalating doses of MGC026 |
| MGC026 Dose for Expansion | BIOLOGICAL | MGC026 recommended dose for expansion |
Inclusion Criteria: * Adults ≥ 18 years old, able to provide informed consent * Adequate performance and laboratory parameters * Availability of archival or formalin-fixed paraffin-embedded tumor tissue sample. Participants may undergo a fresh tumor biopsy to obtain a specimen for testing if an arc...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
MGC026 is an investigational monoclonal antibody being studied in adults with advanced solid tumors. The Phase 1 trial enrolls patients across many cancer types, including non-small cell lung cancer, small-cell lung cancer, head and neck squamous cell carcinoma, bladder cancer, melanoma, gastric cancer, pancreatic cancer, and ovarian cancer.
MGC026 targets B7-H3, a protein expressed on the surface of tumor cells and involved in immune regulation. By binding B7-H3, this monoclonal antibody is designed to act against cancer cells that express the target. It is being developed as an oncology therapeutic for advanced solid tumors.
MGC026 is being developed by MacroGenics, Inc., which trades under the ticker MGNX. The company is sponsoring the clinical program evaluating this monoclonal antibody in patients with advanced solid tumors.
MGC026 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. The ongoing Phase 1 study is designed to evaluate the drug in participants with advanced solid tumors, with enrollment of approximately 250 patients.
MGC026 is being evaluated in one active clinical trial, NCT06242470, titled A Study of MGC026 in Participants With Advanced Solid Tumors. The trial is currently recruiting and plans to enroll about 250 participants across sites in the United States, Australia, and the United Kingdom.
Yes, MGC026 Dose Escalation is another name used for MGC026, the monoclonal antibody developed by MacroGenics. Both names refer to the same investigational drug candidate being studied in the Phase 1 trial NCT06242470 for advanced solid tumors.